OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. McAndrew on Chemotherapy Vs Ovarian Function Suppression in HR+ Breast Cancer

July 29th 2022

Nicholas P. McAndrew, MD, MSCE, discusses the relationship between chemotherapy and ovarian function suppression in hormone receptor–positive, HER2-negative breast cancer.

Dr. Bardia on the Need for Oral SERDs in ESR1-Mutant ER+ Breast Cancer

July 29th 2022

Aditya Bardia, MD, MPH, discusses the need for oral selective estrogen receptor degraders in ESR1-mutant, estrogen receptor–positive breast cancer.

Dr. Baas on Immunotherapy in Mesothelioma Subpopulations

July 29th 2022

Paul Baas, MD, PhD, discusses the benefits of immunotherapy in subpopulations of patients with mesothelioma.

Dr Wagner or the Potential Value of Immunotherapy in Angiosarcoma

July 29th 2022

Michael J. Wagner, MD, explains how immunotherapy may be a promising treatment approach for patients with angiosarcoma.

Dr Wagner on Molecular Pathways in Angiosarcoma

July 29th 2022

Michael J. Wagner, MD, discusses molecular pathways that are becoming relevant in angiosarcoma.

Dr. Wagner on Risk Factors for Angiosarcoma

July 29th 2022

Michael J. Wagner, MD, discusses known risk factors for developing angiosarcoma.

Dr. Wagner on the Standard of Care in Angiosarcoma

July 29th 2022

Michael J. Wagner, MD, discusses the standard of care for patients with angiosarcoma.

Dr. Wagner on Diagnosing Angiosarcoma

July 29th 2022

Michael J. Wagner, MD, discusses the challenge of diagnosing angiosarcoma.

Dr. Wagner on the Value of Cooperative Research Groups in Angiosarcoma

July 29th 2022

Michael J. Wagner, MD, discusses the importance of cooperative research groups in angiocarcinoma.

Dr. Reckamp on Treatment Decisions in MET Exon 14–Mutated NSCLC

July 29th 2022

Karen Reckamp, MD, compares capmatinib and tepotinib, 2 drugs that are approved for the treatment of MET exon 14–mutated non–small cell lung cancer.

Dr. Gandara on the Evaluation of Tumor Biomarkers in NSCLC

July 28th 2022

David R. Gandara, MD, discusses the evaluation of tumor biomarkers in non–small cell lung cancer.

Dr. Massarelli on Unmet Needs in EGFR Exon 20–Mutated NSCLC

July 28th 2022

Erminia Massarelli, MD, PhD, MS, discusses unmet needs in EGFR exon 20–mutated non–small cell lung cancer.

Dr. Subbiah on the FDA Approval of Dabrafenib/Trametinib in BRAF V600E–Mutated Solid Tumors

July 27th 2022

Vivek Subbiah, MD, discusses the FDA approval of dabrafenib plus trametinib for the treatment of patients with BRAF V600E–mutated unresectable or metastatic solid tumors.

Dr. Kahl on the Current Unmet Needs in MCL

July 26th 2022

Brad S. Kahl, MD, discusses unmet needs in mantle cell lymphoma.

Dr. Ryan on the Investigation of Ibrutinib Plus Obinutuzumab in Relapsed/Refractory CLL

July 26th 2022

Christine Ryan, MD, discusses the investigation of ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Dr. Hays on the Importance of Clinical Trials in CRC

July 26th 2022

John L. Hays, MD, PhD, discusses the importance of clinical trials in colorectal cancer.

Dr. Choueiri on the Use of Adjuvant Pembrolizumab in RCC

July 25th 2022

Toni Choueiri, MD, discusses the use of adjuvant pembrolizumab in renal cell carcinoma.

Dr. Wise on Unmet Needs in the Standard of Care in Prostate Cancer

July 25th 2022

David R. Wise, MD, PhD, discusses unmet needs in the standard of care in prostate cancer.

Dr. Strickler on the Rationale of Examining Tucatinib with Trastuzumab in HER2+ CRC

July 25th 2022

John H. Strickler, MD, discusses the rationale of tucatinib plus trastuzumab in HER2-positive colorectal cancer.

Dr. Jatoi on SLN Biopsy in ER-Positive, HER2-Negative Breast Cancer

July 25th 2022

Ismail Jatoi, MD, discusses the importance of individualized care when deciding whether to omit sentinel lymph node biopsy in patients over the age of 70 with clinically node-negative, estrogen receptor–positive, HER2-negative breast cancer.